Novartis' Entresto may have been approved by the FDA for harder-to-treat heart failure patients (those with preserved ejection fraction) back in February, but Eli Lilly was keen on Tuesday to tout Jardiance as the "first and only clinically proven therapy to improve outcomes for the full spectrum of heart failure patients regardless of ejection fraction," when announcing positive top-line data from the Phase III EMPEROR-Preserved study.
This is a less than subtle nod to the fact that Entresto, well established for the treatment of heart failure in patients with reduced ejection fraction, failed to meet its Phase III primary endpoint when evaluated in preserved ejection patients, but was approved in this setting as the FDA believes the totality of data suggests it is a valuable treatment option.
In light of the new Jardiance data, we are fielding a snap-poll to US cardiologists to provisionally ascertain how the future approval of this drug could impact the treatment landscape for heart failure. We are asking the following questions…
Survey results and analysis will be published later this week for FirstWord Pharma PLUS subscribers and can be purchased by non-FirstWord Pharma PLUS subscribers. To be notified when they become available, click here
To read more Physician Views Poll Results articles, click here.